Chris Francis Sells 33,194 Shares of WAVE Life Sciences (NASDAQ:WVE) Stock

WAVE Life Sciences Ltd. (NASDAQ:WVE) insider Chris Francis sold 33,194 shares of the stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $15.05, for a total transaction of $499,569.70. Following the completion of the sale, the insider directly owned 61,867 shares in the company, valued at approximately $931,098.35. This represents a 34.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Chris Francis also recently made the following trade(s):

• On Monday, February 9th, Chris Francis sold 1,883 shares of WAVE Life Sciences stock. The stock was sold at an average price of $13.45, for a total transaction of $25,326.35.
• On Friday, January 2nd, Chris Francis sold 9,375 shares of WAVE Life Sciences stock. The stock was sold at an average price of $16.03, for a total transaction of $150,281.25.
• On Monday, December 8th, Chris Francis sold 441,031 shares of WAVE Life Sciences stock. The shares were sold at an average price of $14.57, for a total value of $6,425,821.67.

WAVE Life Sciences Price Performance

Shares of NASDAQ WVE opened at $13.93 on Friday. The business has a 50-day moving average of $14.45 and a two-hundred day moving average of $10.81. The company has a market capitalization of $2.33 billion, a price-to-earnings ratio of -11.42 and a beta of -1.78. WAVE Life Sciences Ltd. has a 1 year low of $5.28 and a 1 year high of $21.73.

WAVE Life Sciences (NASDAQ:WVE) last released its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.02). The business had revenue of $17.25 million during the quarter. WAVE Life Sciences had a negative net margin of 478.35% and a negative return on equity of 140.75%. As a group, equities research analysts expect that WAVE Life Sciences Ltd. will post -1.14 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of WVE. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of WAVE Life Sciences by 9.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 57,349 shares of the company’s stock worth $463,000 after purchasing an additional 4,957 shares during the period. Goldman Sachs Group Inc. raised its position in WAVE Life Sciences by 3.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 557,644 shares of the company’s stock worth $4,506,000 after buying an additional 20,624 shares during the last quarter. Teacher Retirement System of Texas lifted its stake in shares of WAVE Life Sciences by 8.2% in the 2nd quarter. Teacher Retirement System of Texas now owns 28,955 shares of the company’s stock worth $188,000 after acquiring an additional 2,206 shares during the period. Emerald Mutual Fund Advisers Trust lifted its stake in shares of WAVE Life Sciences by 0.3% in the 2nd quarter. Emerald Mutual Fund Advisers Trust now owns 1,937,489 shares of the company’s stock worth $12,594,000 after acquiring an additional 6,669 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in shares of WAVE Life Sciences by 93.3% in the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 36,097 shares of the company’s stock valued at $235,000 after acquiring an additional 17,424 shares in the last quarter. Institutional investors and hedge funds own 89.73% of the company’s stock.

Trending Headlines about WAVE Life Sciences

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: INHBE obesity program progressing — Wave is advancing WVE‑007 (INHBE GalNAc‑siRNA) and is positioning it as a once‑ or twice‑yearly obesity treatment; early data show fat loss at three months similar to GLP‑1s while preserving muscle, which if confirmed could be a high‑value, low‑frequency dosing differentiator. Wave Life Sciences targets once or twice yearly obesity treatment as INHBE program advances
• Positive Sentiment: On track for near‑term clinical readout — Company press release reiterates INLIGHT data update expected in 1Q 2026 and highlights durable fat‑loss signals and dose‑response expectations for WVE‑007, providing a clear upcoming catalyst. Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Neutral Sentiment: Q4 call and transcript show mixed messaging — Management walked through a revenue beat but flagged pressures and gave operational context on the pipeline; the call transcript and highlight pieces provide detail for modeling near‑term revenue and R&D cadence. Wave Life Sciences Ltd. (WVE) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Earnings miss and weak profitability metrics — WVE reported Q4 EPS of ($0.30), missing consensus by $0.02, though revenue of $17.25M topped expectations; the company still shows large negative margins and negative ROE, underscoring continued cash burn and dilution risk. Wave Life Sciences (WVE) Reports Q4 Loss, Tops Revenue Estimates
• Negative Sentiment: Insider sale by a senior executive — Chris Francis sold 33,194 shares (~$15.05 avg), cutting his ownership nearly 35%; while insider sales can be for personal reasons, markets often interpret sizable reductions by executives as a near‑term negative signal. Chris Francis insider sale

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on WVE shares. Wells Fargo & Company lowered their target price on shares of WAVE Life Sciences from $29.00 to $27.00 and set an “overweight” rating for the company in a report on Thursday, February 12th. UBS Group set a $32.00 price objective on shares of WAVE Life Sciences in a research note on Tuesday, December 16th. Oppenheimer raised their price objective on WAVE Life Sciences from $24.00 to $32.00 and gave the stock an “outperform” rating in a report on Tuesday, December 16th. Leerink Partners reissued an “outperform” rating on shares of WAVE Life Sciences in a report on Monday, December 8th. Finally, HC Wainwright raised their price target on WAVE Life Sciences from $22.00 to $30.00 and gave the stock a “buy” rating in a research note on Friday, December 19th. Thirteen investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, WAVE Life Sciences currently has an average rating of “Moderate Buy” and an average target price of $33.00.

WAVE Life Sciences Company Profile

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.